Ipamorelin 5mg. Used to support growth hormone release, muscle recovery, sleep quality, and healthy body composition. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDepends on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHS-R1a) agonist, the most receptor selective GHRP in the research literature, distinguished from GHRP-2, GHRP-6, and Hexarelin by its highly targeted activity profile that produces GH secretion with minimal influence on cortisol, prolactin, ACTH, or aldosterone. Hudson Science’s 5mg lyophilized vial delivers a lower concentration presentation than the iLab Pharma 10mg Ipamorelin vial. Suited to researchers initiating Ipamorelin protocols, conducting dose response characterization at conservative concentration points, or requiring a supply volume matched to shorter duration research timelines.
The 5mg and 10mg Ipamorelin vials serve distinct research procurement purposes within CSD’s Ipamorelin range. The 5mg Hudson Science format provides the lowest standalone concentration entry point; particularly relevant for protocols beginning at conservative GHS-R1a activation levels before dose escalation, or for combination research with CJC-1295 where the CJC-IPA Blend is unavailable and individual compound ratio control is required. The 10mg iLab Pharma format suits extended protocols and multi group designs requiring greater compound availability per vial. Both are also available as the pre combined Hudson Science CJC-IPA Blend for researchers preferring standardized co administration over individual compound sourcing.
Ipamorelin’s exceptional GHS-R1a selectivity, producing GH release with documented minimal cortisol, prolactin, and ACTH effects. Makes it the preferred GHRP reference compound for research specifically isolating pituitary somatotroph GHS-R1a activation from secondary hormonal variables. CSD’s complete GHRP range covers four distinct selectivity and potency profiles. Ipamorelin’s clean selectivity, GHRP-2’s superior potency with moderate secondary hormonal effects, GHRP-6’s pronounced appetite stimulation through ghrelin pathway activation, and Hexarelin’s maximum GH potency with additional CD36 cardiac receptor activity giving researchers access to the full GHS-R1a agonist spectrum from a single verified Canadian supplier.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s Ipamorelin meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside CJC-1295 and Tesamorelin in comparative GH secretagogue combination and GHS-R1a selectivity studies. Browse CSD’s full peptide range for complete sourcing.
Ipamorelin is a synthetic five amino acid growth hormone secretagogue developed to stimulate endogenous growth hormone release. It acts through the growth hormone secretagogue receptor pathway and has been studied for its effects on pituitary growth hormone secretion and GH related endocrine signaling. This product contains 5mg of lyophilized Ipamorelin in a single vial for laboratory research.
Ipamorelin is primarily researched for growth hormone secretion, pituitary function, growth hormone secretagogue receptor activity, and regulation of the GH/IGF-1 axis. Human pharmacodynamic research has demonstrated a dose related growth hormone response following Ipamorelin exposure, while preclinical studies have also investigated its selectivity compared with earlier growth hormone releasing peptides.
Ipamorelin acts through the growth hormone secretagogue receptor pathway, which participates in hypothalamic and pituitary regulation of growth hormone secretion. Receptor activation promotes release of endogenous growth hormone from pituitary somatotroph cells. Human research has shown a single measurable episode of growth hormone release following Ipamorelin administration, with concentrations subsequently returning toward baseline.
Ipamorelin, GHRP-2, and GHRP-6 are all growth hormone secretagogues, but their endocrine selectivity differs. Comparative experimental research found that Ipamorelin strongly stimulated growth hormone while producing substantially less ACTH and cortisol release than GHRP-2 and GHRP-6. This comparatively selective GH releasing profile is one of the defining characteristics of Ipamorelin.
Yes! This batch is HPLC tested to verify Ipamorelin identity and content accuracy at 5mg per vial. A certificate of analysis is available.
